Abstract
In order to evaluate the immunogenicity and the effect of a virosomal influenza vaccine on viral replication and T-cell activation in HIV-infected children receiving highly active antiretroviral therapy (HAART), 29 children infected with HIV-1 vertically (19 primed with a previous influenza vaccination and 10 who were not been immunized against influenza) were immunized with an intramuscular virosome-adjuvanted influenza vaccine. According to the European Agency for Evaluation of Medical Products (EMEA) criteria, the immunogenicity of the vaccine was adequate against all three influenza strains (A H1N1, A H3N2, and B) in the primed children, and against A H1N1 and AH3N2 in the unprimed children. After in vitro stimulation with vaccine antigens, the IFN-γ levels in the peripheral blood mononuclear cells cultures increased significantly from a baseline level of 103.0±229.8 pg/ml to a 30-day level of 390.7±606.3 pg/ml (P <0.05), with concentrations significantly higher (P <0.05) in the primed children than in the unprimed children. No increase in plasma HIV-1 RNA or HIV-1 proviral DNA was observed in either subgroup, and the immunophenotype analyses demonstrated that the CD4 + cell counts and percentages, the CD4/CD8 ratio and activated lymphocytes remained stable in either group from baseline to 1 month after each vaccine dose. This study showed that the virosomal influenza vaccine does seem to be immunogenic in the majority of HIV-infected children receiving HAART and does not induce viral replication or T-cell activation. Given the possible influenza-related complications in children infected with HIV, these results support the use of this influenza vaccine in such patients.
| Original language | English |
|---|---|
| Pages (from-to) | 440-445 |
| Number of pages | 6 |
| Journal | Journal of Medical Virology |
| Volume | 78 |
| Issue number | 4 |
| DOIs | |
| Publication status | Published - Apr 2006 |
Fingerprint
Keywords
- Children
- HIV
- Immunogenicity
- Influenza vaccine
- T-cell activation
- Viral replication
ASJC Scopus subject areas
- Virology
Cite this
Immunogenicity and effect of a virosomal influenza vaccine on viral replication and T-cell activation in HIV-infected children receiving highly active antiretroviral therapy. / Tanzi, Elisabetta; Esposito, Susanna; Bojanin, Jelena; Amendola, Antonella; Trabattoni, Daria; Pariani, Elena; Pinzani, Raffaella; Zanetti, Alessandro; Principi, Nicola.
In: Journal of Medical Virology, Vol. 78, No. 4, 04.2006, p. 440-445.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Immunogenicity and effect of a virosomal influenza vaccine on viral replication and T-cell activation in HIV-infected children receiving highly active antiretroviral therapy
AU - Tanzi, Elisabetta
AU - Esposito, Susanna
AU - Bojanin, Jelena
AU - Amendola, Antonella
AU - Trabattoni, Daria
AU - Pariani, Elena
AU - Pinzani, Raffaella
AU - Zanetti, Alessandro
AU - Principi, Nicola
PY - 2006/4
Y1 - 2006/4
N2 - In order to evaluate the immunogenicity and the effect of a virosomal influenza vaccine on viral replication and T-cell activation in HIV-infected children receiving highly active antiretroviral therapy (HAART), 29 children infected with HIV-1 vertically (19 primed with a previous influenza vaccination and 10 who were not been immunized against influenza) were immunized with an intramuscular virosome-adjuvanted influenza vaccine. According to the European Agency for Evaluation of Medical Products (EMEA) criteria, the immunogenicity of the vaccine was adequate against all three influenza strains (A H1N1, A H3N2, and B) in the primed children, and against A H1N1 and AH3N2 in the unprimed children. After in vitro stimulation with vaccine antigens, the IFN-γ levels in the peripheral blood mononuclear cells cultures increased significantly from a baseline level of 103.0±229.8 pg/ml to a 30-day level of 390.7±606.3 pg/ml (P <0.05), with concentrations significantly higher (P <0.05) in the primed children than in the unprimed children. No increase in plasma HIV-1 RNA or HIV-1 proviral DNA was observed in either subgroup, and the immunophenotype analyses demonstrated that the CD4 + cell counts and percentages, the CD4/CD8 ratio and activated lymphocytes remained stable in either group from baseline to 1 month after each vaccine dose. This study showed that the virosomal influenza vaccine does seem to be immunogenic in the majority of HIV-infected children receiving HAART and does not induce viral replication or T-cell activation. Given the possible influenza-related complications in children infected with HIV, these results support the use of this influenza vaccine in such patients.
AB - In order to evaluate the immunogenicity and the effect of a virosomal influenza vaccine on viral replication and T-cell activation in HIV-infected children receiving highly active antiretroviral therapy (HAART), 29 children infected with HIV-1 vertically (19 primed with a previous influenza vaccination and 10 who were not been immunized against influenza) were immunized with an intramuscular virosome-adjuvanted influenza vaccine. According to the European Agency for Evaluation of Medical Products (EMEA) criteria, the immunogenicity of the vaccine was adequate against all three influenza strains (A H1N1, A H3N2, and B) in the primed children, and against A H1N1 and AH3N2 in the unprimed children. After in vitro stimulation with vaccine antigens, the IFN-γ levels in the peripheral blood mononuclear cells cultures increased significantly from a baseline level of 103.0±229.8 pg/ml to a 30-day level of 390.7±606.3 pg/ml (P <0.05), with concentrations significantly higher (P <0.05) in the primed children than in the unprimed children. No increase in plasma HIV-1 RNA or HIV-1 proviral DNA was observed in either subgroup, and the immunophenotype analyses demonstrated that the CD4 + cell counts and percentages, the CD4/CD8 ratio and activated lymphocytes remained stable in either group from baseline to 1 month after each vaccine dose. This study showed that the virosomal influenza vaccine does seem to be immunogenic in the majority of HIV-infected children receiving HAART and does not induce viral replication or T-cell activation. Given the possible influenza-related complications in children infected with HIV, these results support the use of this influenza vaccine in such patients.
KW - Children
KW - HIV
KW - Immunogenicity
KW - Influenza vaccine
KW - T-cell activation
KW - Viral replication
UR - http://www.scopus.com/inward/record.url?scp=33644772845&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33644772845&partnerID=8YFLogxK
U2 - 10.1002/jmv.20559
DO - 10.1002/jmv.20559
M3 - Article
C2 - 16482542
AN - SCOPUS:33644772845
VL - 78
SP - 440
EP - 445
JO - Journal of Medical Virology
JF - Journal of Medical Virology
SN - 0146-6615
IS - 4
ER -